Obstet Gynecol Sci.  2020 Apr;63(3):315-322. 10.5468/ogs.2020.63.3.315.

Recombinant anti-D for prevention of maternal-foetal Rh(D) alloimmunization: a randomized multi-centre clinical trial

• Mayekar RV
• Paradkar G
• Bhosale AA
• Sachan R
• Beeram S
• Anand AR
• Mundle SR
• Trivedi Y
• R
• Patole KP
• Sambarey P
• Daftary GV
• John J
• Divekar GH

• KMID: 2500421
• DOI: http://doi.org/10.5468/ogs.2020.63.3.315

Abstract

Objective
To compare the efficacy and safety of recombinant anti-D (R-anti-D) with conventional polyclonal anti-D (Poly anti-D) in preventing maternal-fetal rhesus D (RhD) alloimmunization and to investigate the immunogenicity of R-anti-D.
Methods
This was a randomized, open-label, multi-center clinical trial conducted in RhD-negative pregnant women who did not receive antenatal anti-D who delivered RhD-positive babies and showed negative indirect Coombs tests (ICTs) at baseline. The women were randomized in a 2:1 ratio to R-anti-D or Poly anti-D groups and were administered 300 mcg (IM) of the corresponding drug within 72 hours of delivery. ICT was performed 72 hours, 90 days, and 180 days after anti-D injection. Serum samples were collected to check for the development of antibodies against R-anti-D at days 90 and 180, using bridging enzyme-linked immunosorbent assay. The proportion of subjects who had positive ICT results at days 90 and 180 were compared between the groups using Fisher’s exact test.
Results
A total of 144 women were randomized to the R-anti-D group and 71 to the Poly anti-D group. Three women in the R-anti-D and none in the Poly anti-D group had a positive ICT result at day 90. No woman in either group had positive ICT result at day 180. Both drugs were well tolerated with only 4 reports of adverse events in each group—all were mild, non-serious, and resolved without sequelae. No subject developed antibodies against R-anti-D.
Conclusion
The studied R-anti-D is comparable in efficacy to conventional Poly anti-D and is safe and non-immunogenic. Trial Registration Clinical Trials Registry of India Identifier: CTRI/2017/03/008101

Keyword

Rho(D) immune globulin; Recombinant proteins; Newborn hemolytic disease; Rh isoimmunization

Figure

• 

  Fig. 1 Manufacturing process and link between monoclonal anti-D (Rhoclone®) and recombinant anti-D.

• 

  Fig. 2 Principle of biotin-digoxigenin complex-based bridging ELISA to test the immunogenicity of R-anti-D.ADA, antidrug antibody; R-anti-D, recombinant anti-D; HRP, horseradish peroxidase; TMB, tetramethylbenzidine; ELISA, enzyme-linked immunosorbent assay.

• 

  Fig. 3 Trial and participant flow. One subject from the R-anti-D group and 4 subjects from the Poly anti-D group were excluded from efficacy analysis owing to major protocol deviations.R-anti-D, recombinant anti-D; Poly anti-D, polyclonal anti-D; F/U, followed-up.

Reference

1. Bennardello F, Coluzzi S, Curciarello G, Todros T, Villa S. Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) and Italian Society of Gynaecology and Obstetrics (SIGO) working group. Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn. Blood Transfus. 2015; 13:109–134. PMID: 25633877.

2. Zimring JC, Hudson KE. Cellular immune responses in red blood cell alloimmunization. Hematology Am Soc Hematol Educ Program. 2016; 2016:452–456. PMID: 27913515.

3. Agarwal K, Rana A, Ravi AK. Treatment and prevention of Rh isoimmunization. J Fetal Med. 2014; 1:81–88.

4. Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program. 2015; 2015:146–151. PMID: 26637714.

5. Qureshi H, Massey E, Kirwan D, Davies T, Robson S, White J, et al. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med. 2014; 24:8–20. PMID: 25121158.

6. Kent J, Farrell AM, Soothill P. Routine administration of anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice. BMC Pregnancy Childbirth. 2014; 14:87. PMID: 24568571.

7. Minon JM, Gerard CH, Chantraine F, Nisolle M. Anti-D prophylaxis reviewed in the erea of foetal RHD genotyping. J Blood Disord Transfus. 2015; 6:1–6.

8. Brinc D, Lazarus AH. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. Hematology Am Soc Hematol Educ Program. 2009; 2009:185–191.

9. Holzlöhner P, Hanack K. Generation of murine monoclonal antibodies by hybridoma technology. J Vis Exp. 2017; 119:e54832.

10. Gstraunthaler G, Lindl T, van der Valk J. A plea to reduce or replace fetal bovine serum in cell culture media. Cytotechnology. 2013; 65:791–793. PMID: 23975256.

11. European Medicines Agency. Guideline on the clinical investigation of human anti-D immunoglobulin for intravenous and/or intramuscular use [Internet]. London: Committee for Medicinal Products for Human Use, European Medicines Agency;c2007. cited 2018 Dec 4. Available from: https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-investigation-human-anti-d-immunoglobulin-intravenous/intramuscular-use_en.pdf.

12. Crowther C, Middleton P. Anti-D administration after childbirth for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev. 2000; CD000021. PMID: 10796089.

13. McBain RD, Crowther CA, Middleton P. Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev. 2015; CD000020. PMID: 26334436.

14. Dajak S, Roje D, Hašpl ŽH, Maglić PE. The importance of antenatal prevention of RhD immunisation in the first pregnancy. Blood Transfus. 2014; 12:410–415. PMID: 24887219.

15. US Food and Drug Administration. Assay development and validation for immunogenicity testing of therapeutic protein products [Internet]. Silver Spring (MD): USFDA Draft Guidance for Industry;c2016. cited 2019 Jan 17. Available from: https://www.fda.gov/downloads/Drugs/Guidances/UCM192750.pdf.

16. Costumbrado J, Ghassemzadeh S. Incompatibility. In : Abai B, editor. StatPearls. Treasure Island (FL): StatPearls Publishing;2020.

17. Zipursky A, Bhutani VK, Odame I. Rhesus disease: a global prevention strategy. Lancet Child Adolesc Health. 2018; 2:536–542. PMID: 30169325.

18. Reverberi R. The persistence of red cell alloantibodies. Blood Transfus. 2008; 6:225–234. PMID: 19112738.

19. Fiala C, Fux M, Gemzell Danielsson K. Rh-prophylaxis in early abortion. Acta Obstet Gynecol Scand. 2003; 82:892–903. PMID: 12956838.

20. Howard HL, Martlew VJ, McFadyen IR, Clarke CA. Preventing Rhesus D haemolytic disease of the newborn by giving anti-D immunoglobulin: are the guidelines being adequately followed? Br J Obstet Gynaecol. 1997; 104:37–41. PMID: 8988694.

21. Hong F, Ruiz R, Price H, Griffiths A, Malinoski F, Woloski M. Safety profile of WinRho anti-D. Semin Hematol. 1998; 35:9–13.

22. Rutkowski K, Nasser SM. Management of hypersensitivity reactions to anti-D immunoglobulin preparations. Allergy. 2014; 69:1560–1563. PMID: 25066207.